Aldesleukin Terminated Phase 1 / 2 Trials for Metastatic Melanoma / Renal Cancers / Metastatic Cancers Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00923390Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
NCT00923806Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer